High response rate to darbopoetin alfa in "low risk" MDS: Results of a phase II study.

被引：0
|
作者：
Mannone, L [1 ]
Gardin, C [1 ]
Quarre, MC [1 ]
Bernard, JF [1 ]
Giraudier, S [1 ]
Rosenthal, E [1 ]
Vassilief, D [1 ]
Hamza, F [1 ]
Park, S [1 ]
Kiladjian, JJ [1 ]
Vaultier, S [1 ]
Beyne-Rouzy, M [1 ]
Cheze, S [1 ]
Voilliat, L [1 ]
Agape, P [1 ]
Dreyfus, F [1 ]
Fenaux, P [1 ]
机构：
[1] GFM, Paris 13, France
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
69
引用
收藏
页码：24A / 24A
页数：1
相关论文
共 50 条
  • [21] Bortezomib plus low dose cytarabine in Int-2 and high risk MDS. Interim results of a phase I/II trial by the GFM
    Natarajan, Shahti
    Fenaux, Pierre
    Vey, Norbert
    Guerci, A.
    Coulibaly, I.
    Charbonnier, A.
    Ravoet, C.
    Courby, S.
    Etienne, G.
    Chaury, M. P.
    Cheze, S.
    Stamatoullas, A.
    Legros, L.
    Berger, E.
    Lescoute, A.
    Vaultier, S.
    Dreyfus, F.
    BLOOD, 2007, 110 (11) : 435A - 435A
  • [22] TREATMENT WITH VNP40101M (CLORETAZINE?) IN PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES (MDS): RESULTS OF A SUBSET POPULATION IN A PHASE II STUDY
    Mufti, G.
    Rizzieri, D.
    Vey, N.
    Hudak, D.
    Karp, J.
    Giles, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 94 - 95
  • [23] Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS - Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies
    Ades, Lionel
    de Renzis, Benoit
    Jeddi, Ramzi
    Delaunay, Jacques
    Braun, Thorsten
    Berger, Mathilde Hunault
    Stamatoullas, Aspasia
    Sanhes, Laurence
    Samey, Benedicte
    Chermat, Fatiha
    Meddeb, Baklis
    Fenaux, Pierre
    BLOOD, 2012, 120 (21)
  • [24] Effect of deferasirox plus erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial
    Gattermann, Norbert
    Coll, Rosa
    Jacobasch, Lutz
    Allameddine, Allameddine
    Azmon, Amin
    DeBonnett, Laurie
    Bruederle, Andreas
    Jin, Jie
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (02) : 208 - 215
  • [25] High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
    Kelaidi, C.
    Beyne-Rauzy, O.
    Braun, T.
    Sapena, R.
    Cougoul, P.
    Ades, L.
    Pillard, F.
    Lambert, C.
    Charniot, J. C.
    Guerci, A.
    Choufi, B.
    Stamatoullas, A.
    Slama, B.
    De Renzis, B.
    Ame, S.
    Damaj, G.
    Boyer, F.
    Chaury, M. P.
    Legros, L.
    Cheze, S.
    Testu, A.
    Gyan, E.
    Bene, M. C.
    Rose, C.
    Dreyfus, F.
    Fenaux, P.
    ANNALS OF HEMATOLOGY, 2013, 92 (05) : 621 - 631
  • [26] High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
    C. Kelaidi
    O. Beyne-Rauzy
    T. Braun
    R. Sapena
    P. Cougoul
    L. Adès
    F. Pillard
    C. Lambert
    J. C. Charniot
    A. Guerci
    B. Choufi
    A. Stamatoullas
    B. Slama
    B. De Renzis
    S. Ame
    G. Damaj
    F. Boyer
    M. P. Chaury
    L. Legros
    S. Cheze
    A. Testu
    E. Gyan
    M. C. Béné
    C. Rose
    F. Dreyfus
    P. Fenaux
    Annals of Hematology, 2013, 92 : 621 - 631
  • [27] Is there a role for ATRA in combination to EPO in lower risk myelodysplastic syndrome? Preliminary results of a phase II study.
    Ades, L
    Mohamed, H
    Vassilief, D
    Berger, E
    Slama, B
    Vey, N
    Delarue, R
    Beyne-Rauzy, O
    Guerci, A
    Cheze, S
    Thomas, X
    Stamatoullas, A
    Gardembas, M
    Bauduer, F
    Kolb, A
    Chaury, MC
    Legros, L
    Damaj, G
    Hamza, F
    Vaultier, S
    Dreyfus, F
    Fenaux, P
    BLOOD, 2005, 106 (11) : 712A - 713A
  • [28] AZACITIDINE (AZA) COMBINED WITH IDARUBICIN (IDA) IN HIGHER RISK MDS (HRMDS) - RESULTS OF A PHASE I/II STUDY BY THE GFM
    Sebert, M.
    Ades, L.
    Stamatoullas, A.
    Braun, T.
    Delaunay, J.
    de Renzis, B.
    Jeddi, R.
    Meddeb, B.
    Berger, M. Hunault
    Samey, B.
    Chermat, F.
    Chaffaut, C.
    Chevert, S.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S63 - S63
  • [29] Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
    Cortes, Jorge E.
    Smith, B. Douglas
    Wang, Eunice S.
    Merchant, Akil
    Oehler, Vivian G.
    Arellano, Martha
    DeAngelo, Daniel J.
    Pollyea, Daniel A.
    Sekeres, Mikkael A.
    Robak, Tadeusz
    Ma, Weidong Wendy
    Zeremski, Mirjana
    Shaik, M. Naveed
    Laird, A. Douglas
    O'Connell, Ashleigh
    Chan, Geoffrey
    Schroeder, Mark A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (11) : 1301 - 1310
  • [30] Sunitinib malate in advanced hepatocellular carcinoma: Results of a phase II study.
    Barone, C.
    Basso, M.
    Cassano, A.
    Rufini, V.
    D'Argento, E.
    Riccardi, L.
    Schinzari, G.
    Pompili, M.
    Grieco, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345